Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 13 January 2025

Created: 13 January 2025

Last Updated: 13 January 2025

Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’ radiopharmaceutical leadership with addition of Alzheimer’s radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities

Posted: 2025-01-13 05:05:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market - Newscast

Lantheus to acquire Evergreen in $1bn deal to expand radiopharmaceutical pipeline

Thu, 30 Jan 2025 03:01:00 GMT Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Why Lantheus Holdings Stock Got Thrashed on Tuesday

Wed, 29 Jan 2025 01:32:00 GMT Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical ... It wrote in the press release trumpeting the deal that "the addition ...

Why Lantheus Holdings Stock Got Thrashed on Tuesday

Wed, 29 Jan 2025 01:30:04 GMT Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an ...

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio

Tue, 28 Jan 2025 07:32:00 GMT Lantheus strengthens its radiopharmaceutical business with Evergreen and Life Molecular acquisitions, adding oncology and Alzheimer's diagnostics.

Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen

Tue, 28 Jan 2025 06:09:00 GMT On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist Lantheus is placing some serious cash on the dealmaking table. | In a ...